These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38563476)

  • 1. Oral cinacalcet administration decreases serum ionized calcium and parathyroid hormone concentrations in healthy dogs.
    Clark HE; Trepanier LA; Wood MW
    J Vet Pharmacol Ther; 2024 Jul; 47(4):274-279. PubMed ID: 38563476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
    Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
    BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients.
    Sharma AK; Masterson R; Holt SG; Tan SJ; Hughes PD; Chu M; Jayadeva P; Toussaint ND
    Nephrology (Carlton); 2016 Jan; 21(1):46-54. PubMed ID: 26072678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
    Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of preoperative serum concentrations of ionized calcium and parathyroid hormone as predictors of hypocalcemia following parathyroidectomy in dogs with primary hyperparathyroidism: 17 cases (2001-2009).
    Arbaugh M; Smeak D; Monnet E
    J Am Vet Med Assoc; 2012 Jul; 241(2):233-6. PubMed ID: 22765370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.
    Marotta V; Di Somma C; Rubino M; Sciammarella C; Del Prete M; Marciello F; Ramundo V; Circelli L; Buonomano P; Modica R; Vitale M; Colao A; Faggiano A
    Endocrine; 2015 May; 49(1):274-8. PubMed ID: 25123977
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a Hypoparathyroid Male Rodent Model for Testing Delayed-Clearance PTH Molecules.
    Ramezanipour N; Esfahani SHZ; Eastell R; Newell-Price J; Trevitt G; Ross RJ; Wilkinson IR
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34940833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
    Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
    Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
    Akizawa T; Shimazaki R; Fukagawa M;
    PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A step towards cinacalcet testing for the diagnosis of primary hyperparathyroidism: comparison with the standardized intravenous calcium loading. A pilot study.
    Cailleux A; Vuillermet P; Basuyau JP; Ménard JF; Lefebvre H; Kuhn JM; Prévost G
    Clin Endocrinol (Oxf); 2015 May; 82(5):663-9. PubMed ID: 25645432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
    Lee S; Gu N; Kim BH; Lim KS; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 May; 34(5):1160-9. PubMed ID: 22503212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
    Shoback DM; Bilezikian JP; Turner SA; McCary LC; Guo MD; Peacock M
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5644-9. PubMed ID: 14671147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
    Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
    Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgery.
    Misiorowski W; Zgliczyński W
    Endokrynol Pol; 2017; 68(3):306-310. PubMed ID: 28660989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women.
    Boucher A; D'Amour P; Hamel L; Fugère P; Gascon-Barré M; Lepage R; Ste-Marie LG
    J Clin Endocrinol Metab; 1989 Apr; 68(4):831-6. PubMed ID: 2921312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide.
    Yoshimura K; Funakoshi Y; Terawaki H
    Ther Apher Dial; 2018 Oct; 22(5):553-554. PubMed ID: 29927050
    [No Abstract]   [Full Text] [Related]  

  • 20. Cinacalcet for the treatment of primary hyperparathyroidism.
    Sajid-Crockett S; Singer FR; Hershman JM
    Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.